PDCD1 and Hodgkins lymphoma: The expression of tsMHC-II has been related to longer progression free survival (PFS) and overall survival (OS) in melanoma and Hodgkin lymphoma patients treated with programmed death cell 1 (PD-1)/programmed death-ligand 1 (PD-L1) monoclonal antibodies (mAbs) [123,125,126].